The assay was developed in partnership with Merck and is intended as a companion diagnostic for that firm's anti-PD-L1 immunotherapy.
Roche Diagnostics got the nod for its Elecsys Anti-HAV II test for the detection of total antibodies — IgG and IgM — to the hepatitis A virus.
The company plans to use the proceeds to fund the redemption of its outstanding 5.00 percent senior notes due 2020.
Get the latest news from Biovica, Invitae, and Agilent Technologies for the week of 8/30/19.
Agilent has partnered with the National University of Singapore and National University Hospital to establish the S$38 million ($27.4 million) research and development facility in Singapore.
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
The diagnostic can now be used to identify patients with esophageal squamous cell carcinoma who may benefit from first-line treatment with Keytruda.
The diagnostic can now be used to identify patients with head and neck squamous cell carcinoma who may benefit from first-line treatment with Keytruda.
The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.